Cargando…
Liver dysfunction and SARS-CoV-2 infection
Severe acute respiratory syndrome coronavirus 2 infection is the cause of coronavirus disease 2019 (COVID-19), which predominantly affects the respiratory system; it also causes systemic and multi-organic disease. Liver damage is among the main extrapulmonary manifestations. COVID-19-associated live...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311530/ https://www.ncbi.nlm.nih.gov/pubmed/34326607 http://dx.doi.org/10.3748/wjg.v27.i26.3951 |
_version_ | 1783728976269672448 |
---|---|
author | Gracia-Ramos, Abraham Edgar Jaquez-Quintana, Joel Omar Contreras-Omaña, Raúl Auron, Moises |
author_facet | Gracia-Ramos, Abraham Edgar Jaquez-Quintana, Joel Omar Contreras-Omaña, Raúl Auron, Moises |
author_sort | Gracia-Ramos, Abraham Edgar |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 infection is the cause of coronavirus disease 2019 (COVID-19), which predominantly affects the respiratory system; it also causes systemic and multi-organic disease. Liver damage is among the main extrapulmonary manifestations. COVID-19-associated liver injury is defined as any liver damage occurring during the disease course and treatment of COVID-19 in patients with or without pre-existing liver disease, and occurs in approximately one in five patients. Abnormal liver test results have been associated with a more severe course of COVID-19 and other complications, including death. Mechanisms linking COVID-19 to liver injury are diverse. Particular consideration should be made for patients with pre-existing liver disease, such as metabolic dysfunction-associated fatty liver disease, chronic liver disease due to viral or autoimmune disease, liver transplant carriers, or cirrhosis, given the risk for more severe outcomes. This manuscript summarizes the current lines of evidence on COVID-19-associated liver injury regarding pathophysiology, clinical significance, and management in both patients with or without pre-existing liver disease, to facilitate clinicians’ access to updated information and patient care. Finally, we mention the ideas and recommendations to be considered for future research. |
format | Online Article Text |
id | pubmed-8311530 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-83115302021-07-28 Liver dysfunction and SARS-CoV-2 infection Gracia-Ramos, Abraham Edgar Jaquez-Quintana, Joel Omar Contreras-Omaña, Raúl Auron, Moises World J Gastroenterol Frontier Severe acute respiratory syndrome coronavirus 2 infection is the cause of coronavirus disease 2019 (COVID-19), which predominantly affects the respiratory system; it also causes systemic and multi-organic disease. Liver damage is among the main extrapulmonary manifestations. COVID-19-associated liver injury is defined as any liver damage occurring during the disease course and treatment of COVID-19 in patients with or without pre-existing liver disease, and occurs in approximately one in five patients. Abnormal liver test results have been associated with a more severe course of COVID-19 and other complications, including death. Mechanisms linking COVID-19 to liver injury are diverse. Particular consideration should be made for patients with pre-existing liver disease, such as metabolic dysfunction-associated fatty liver disease, chronic liver disease due to viral or autoimmune disease, liver transplant carriers, or cirrhosis, given the risk for more severe outcomes. This manuscript summarizes the current lines of evidence on COVID-19-associated liver injury regarding pathophysiology, clinical significance, and management in both patients with or without pre-existing liver disease, to facilitate clinicians’ access to updated information and patient care. Finally, we mention the ideas and recommendations to be considered for future research. Baishideng Publishing Group Inc 2021-07-14 2021-07-14 /pmc/articles/PMC8311530/ /pubmed/34326607 http://dx.doi.org/10.3748/wjg.v27.i26.3951 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Frontier Gracia-Ramos, Abraham Edgar Jaquez-Quintana, Joel Omar Contreras-Omaña, Raúl Auron, Moises Liver dysfunction and SARS-CoV-2 infection |
title | Liver dysfunction and SARS-CoV-2 infection |
title_full | Liver dysfunction and SARS-CoV-2 infection |
title_fullStr | Liver dysfunction and SARS-CoV-2 infection |
title_full_unstemmed | Liver dysfunction and SARS-CoV-2 infection |
title_short | Liver dysfunction and SARS-CoV-2 infection |
title_sort | liver dysfunction and sars-cov-2 infection |
topic | Frontier |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311530/ https://www.ncbi.nlm.nih.gov/pubmed/34326607 http://dx.doi.org/10.3748/wjg.v27.i26.3951 |
work_keys_str_mv | AT graciaramosabrahamedgar liverdysfunctionandsarscov2infection AT jaquezquintanajoelomar liverdysfunctionandsarscov2infection AT contrerasomanaraul liverdysfunctionandsarscov2infection AT auronmoises liverdysfunctionandsarscov2infection |